Intellia Therapeutics, Inc. announced the appointment of Muna Bhanji to its board of directors. Ms. Bhanji brings more than 30 years of strategic and operational experience in the biopharmaceutical industry to Intellias board, including a proven track record of driving growth across a broad portfolio of medicines and vaccines. She built her career at Merck &Co., where she held several senior leadership roles within U.S. based sales, marketing, managed markets and commercial operations, global franchise business units, and global market access and policy.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.73 USD | -0.96% | +6.31% | -25.45% |
Jun. 03 | Intellia Therapeutics Shares Rise as NTLA-2002 Phase 1 Study Observes 98% Mean Reduction in Monthly Attack Rate | MT |
Jun. 03 | Transcript : Intellia Therapeutics, Inc. - Special Call |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.45% | 2.21B | |
+51.85% | 59.28B | |
+41.42% | 40.94B | |
-5.25% | 40.17B | |
-5.16% | 28.69B | |
+12.79% | 26.63B | |
-20.18% | 18.89B | |
+30.88% | 12.46B | |
+0.61% | 12.42B | |
+25.06% | 12.26B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Intellia Therapeutics, Inc. Names Muna Bhanji to Its Board of Directors